Unfortunately, an estimated 2,500 people have died.īleeding linked to these anticoagulants is life-threatening. Since 2010, more than 15,000 people have been hospitalized from bleeding side effects related to Xarelto, Eliquis or Pradaxa. The next-generation blood thinners are prescribed to more than 6 million patients, with a growing number of individuals experiencing bleeding as a side effect. New-age blood thinners hit the market as alternatives to Warfarin, a traditional anticoagulant requiring regular maintenance of blood tests and diet restrictions. The medications are also prescribed after knee or hip replacement surgeries. The newer blood thinners protect against stroke in patients with atrial fibrillation and prevent deep vein thrombosis (DVT) and pulmonary embolism. Next-generation anticoagulants work by selectively inhibiting Factor Xa, a blood enzyme that assists in clotting.

Known as AndexXa, the reversal agent has been moving through the Food and Drug Administration (FDA) approval process. Portola Pharmaceuticals has worked to manufacture a medication to reverse the life-threatening, uncontrollable bleeding. Unlike Warfarin, these next-generation anticoagulants don’t offer an antidote. In 2015, more than 80,000 individuals using blood thinners like Xarelto and Eliquis were hospitalized due to an extreme bleeding side effect.

Andexxa side effects